APA

Unger J. M., Griffin K., Donaldson G. W., Baranowski K. M., Good M. J., Reburiano E., Hussain M., Monk P. J., Van Veldhuizen P. J., Carducci M. A., Higano C. S., Lara P. N., Tangen C. M., Quinn D. I., Wade J. L., Vogelzang N. J., Thompson I. M. & Moinpour C. M. (2017). Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). : Journal of patient-reported outcomes.

Chicago

Unger Joseph M, Griffin Katherine, Donaldson Gary W, Baranowski Karen M, Good Margorie J, Reburiano Eunicia, Hussain Maha, Monk Paul J, Van Veldhuizen Peter J, Carducci Michael A, Higano Celestia S, Lara Primo N, Tangen Catherine M, Quinn David I, Wade James L, Vogelzang Nicholas J, Thompson Ian M and Moinpour Carol M. 2017. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). : Journal of patient-reported outcomes.

Harvard

Unger J. M., Griffin K., Donaldson G. W., Baranowski K. M., Good M. J., Reburiano E., Hussain M., Monk P. J., Van Veldhuizen P. J., Carducci M. A., Higano C. S., Lara P. N., Tangen C. M., Quinn D. I., Wade J. L., Vogelzang N. J., Thompson I. M. and Moinpour C. M. (2017). Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). : Journal of patient-reported outcomes.

MLA

Unger Joseph M, Griffin Katherine, Donaldson Gary W, Baranowski Karen M, Good Margorie J, Reburiano Eunicia, Hussain Maha, Monk Paul J, Van Veldhuizen Peter J, Carducci Michael A, Higano Celestia S, Lara Primo N, Tangen Catherine M, Quinn David I, Wade James L, Vogelzang Nicholas J, Thompson Ian M and Moinpour Carol M. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). : Journal of patient-reported outcomes. 2017.